Investigational drug · Phase 2
SCB-1019T
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for RSV Infection, Human Metapneumovirus Infection, Parainfluenza Infection.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "SCB-1019T"
First trial start
2025
Jun 18, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SCB-1019T", any sponsor or status.
Conditions studied
As listed on its trial records.
- RSV Infection
- Human Metapneumovirus Infection
- Parainfluenza Infection
Approved drugs for the same conditions: Influenza · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "SCB-1019T" as an intervention, largest first.
- Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older AdultsPivotal-lookingActive, not recruiting
Clover Biopharmaceuticals AUS PtyIndustry
NCT06984094 · 612 participants · Start Jun 18, 2025 · Primary completion Mar 2028
Drug: SCB-1019T; SCB-1022 and 2 more · For: RSV Infection; Human Metapneumovirus Infection; Parainfluenza Infection
Sites: Adelaide, Australia; Melbourne, Australia; Perth, Australia
- Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy AdultsPivotal-lookingRecruiting
Clover Biopharmaceuticals USA, LLCIndustry
NCT06843317 · 160 participants (planned) · Start Mar 21, 2025 · Primary completion Mar 3, 2026
Drug: Candidate vaccine, SCB-1019T; AREXVY · For: RSV Infection
Sites: Phoenix, Arizona; Fort Myers, Florida; Lexington, Kentucky · 5 sites in all
- First-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy AdultsPivotal-lookingCompleted
Clover Biopharmaceuticals AUS PtyIndustry
NCT06194318 · 160 participants · Start Dec 13, 2023 · Primary completion Feb 26, 2025
Drug: Candidate vaccine, SCB-1019; placebo and 2 more · For: Respiratory Syncytial Virus Vaccination
Sites: Adelaide, Australia; Nedlands, Australia
Clover Biopharmaceuticals AUS PtyIndustry
NCT06666179 · 0 participants · Start Oct 2025 · Primary completion Jun 2026
Drug: low dose SCB-1019T; adjuvanted low dose SCB-1019T and 2 more · For: RSV Infection
Sites: Perth, Australia
Newest research
PubMed records naming it or its code names, newest first.
- A Novel Unadjuvanted Subunit Respiratory Syncytial Virus Prefusion F Vaccine Induces Potent and Differentiated Functional Immune Responses Compared to AS01-Adjuvanted Arexvy in Older Adults.
Richmond P, Kwan TTL, Rook C, et al. · Open Forum Infect Dis 2026
Also in development for RSV Infection
- RSVpreFRESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE, PF-06928316Phase 38 trials
Pfizer · Respiratory Syncytial Virus (RSV), Lower Respiratory Tract Illness, Adult
- zelicapavirPhase 32 trials
Enanta Pharmaceuticals, Inc · RSV, RSV Infection, Respiratory Syncytial Virus (RSV)
- EDP-938Phase 21 trial
Enanta Pharmaceuticals, Inc · RSV Infection
- SCB-1022Phase 21 trial
Clover Biopharmaceuticals AUS Pty · RSV Infection, Human Metapneumovirus Infection, Parainfluenza Infection
- SCB-1033Phase 21 trial
Clover Biopharmaceuticals AUS Pty · RSV Infection, Human Metapneumovirus Infection, Parainfluenza Infection
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.